Treatment of XXXX with @entity1524 ( @entity1524 ) and @entity4444 : a pilot study.

@entity1 @entity4444 @entity137 @entity5 @entity1524 @entity1358 @entity703
Forty-five @entity1 with @entity1358 were treated with @entity1524 ( @entity1524 ) and @entity4444 . @entity1 received @entity1524 , 100 mg orally daily; @entity4444 administration, 300 mg orally four times daily, was initiated on day 15 of therapy, and treatment with both drugs was continued until progression of disease. Three @entity1 are too early to evaluate (on study less than or equal to 2 months with no change in @entity5 status). Objective responses (greater than or equal to 50% reduction in measurable disease) occurred in 14 of 42 evaluable @entity1 (33.3%) (the 95% confidence interval based on this rate is +/- 14.3%), with three complete responses and 11 partial responses (PR). Complete responses lasted 9.5, 4+, and 9.5+ months. The median duration of response for the PR group was 5 months (range, 4 to 21+ months). Twelve @entity1 experienced stabilization of disease ranging from 4 to 16.5+ months. No response was seen in 16 @entity1 . There was no symptomatic, hematologic, or chemical (organ dysfunction) @entity137 among the 45 @entity1 treated. @entity1524 and @entity4444 appear to be safe and active agents in the treatment of metastatic @entity703 . Further studies are required to determine the optimal dose and scheduling of these agents.
